newsfilter
← Latest News
GlobeNewswire·

The British Journal of Dermatology Publishes Results from Amryt's EASE Phase 3 Trial in Epidermolysis Bullosa

The British Journal of Dermatology Publishes Results from Amryt's EASE Phase 3 Trial in Epidermolysis Bullosa DUBLIN, Ireland, and Boston MA, October 25, 2022 Amryt (NASDAQ:AMYT), a global, commercial-stage